A venture capital firm based in the US manages a total of $85 million in assets and is currently making investments out of its vintage 2017 fund. The firm is raising Fund IV that will close in the third quarter of 2023, and anticipates an additional $50 million of assets under management. The firm provides from $1-$7 million of its own capital to chosen companies and can leverage its network of investors to provide up to $10 million over the life of the investment. The firm looks to invest in companies located in the US except for NYC north and Silicon Valley north and plans to invest in 2-3 companies over the next year.
The firm is looking for Life Science companies primarily in areas of Medical Technology, Diagnostics and B2B Digital Health although the firm will also consider companies with developed and approved therapeutics. The firm is open to all subsectors and indications within these areas but prefers orthopedics and cardiovascular.
Ideal companies have $1 million or more of run-rate revenue; gross margins of 50% or higher; and equity capital needs of less than $10 million at the time of investment. The firm looks to take a board seat into companies and take a very active role in helping the company expand through their network of strategic partners.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment